Boyapati R - Search Results

1

Boyapati R, Satsangi J, Ho GT. Boyapati R, et al. F1000Prime Rep. 2015 Apr 2;7:44. doi: 10.12703/P7-44. eCollection 2015. F1000Prime Rep. 2015. PMID: 26097717 Free PMC article. Review.

2

Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.

Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel JF, Satsangi J. Torres J, et al. Gastroenterology. 2015 Dec;149(7):1716-30. doi: 10.1053/j.gastro.2015.08.055. Epub 2015 Sep 14. Gastroenterology. 2015. PMID: 26381892 Free article. Review.

3

Editorial: what can be done when infliximab stops working in ulcerative colitis?

Boyapati RK, Ho GT, Satsangi J. Boyapati RK, et al. Aliment Pharmacol Ther. 2016 Jan;43(1):164. doi: 10.1111/apt.13422. Aliment Pharmacol Ther. 2016. PMID: 26638930 Free article. No abstract available.

4

Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications.

Boyapati RK, Rossi AG, Satsangi J, Ho GT. Boyapati RK, et al. Mucosal Immunol. 2016 May;9(3):567-82. doi: 10.1038/mi.2016.14. Epub 2016 Mar 2. Mucosal Immunol. 2016. PMID: 26931062 Free article. Review.

5

Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases.

Kalla R, Kennedy NA, Ventham NT, Boyapati RK, Adams AT, Nimmo ER, Visconti MR, Drummond H, Ho GT, Pattenden RJ, Wilson DC, Satsangi J. Kalla R, et al. Among authors: boyapati rk. Am J Gastroenterol. 2016 Dec;111(12):1796-1805. doi: 10.1038/ajg.2016.342. Epub 2016 Sep 6. Am J Gastroenterol. 2016. PMID: 27596694

6

Biomarkers in Search of Precision Medicine in IBD.

Boyapati RK, Kalla R, Satsangi J, Ho GT. Boyapati RK, et al. Am J Gastroenterol. 2016 Dec;111(12):1682-1690. doi: 10.1038/ajg.2016.441. Epub 2016 Sep 27. Am J Gastroenterol. 2016. PMID: 27670602 Review.

7

Can Thiopurines Prevent Formation of Antibodies Against Tumor Necrosis Factor Antagonists After Failure of These Therapies?

Boyapati RK, Ho GT, Satsangi J. Boyapati RK, et al. Clin Gastroenterol Hepatol. 2017 Jan;15(1):76-78. doi: 10.1016/j.cgh.2016.09.152. Epub 2016 Oct 5. Clin Gastroenterol Hepatol. 2017. PMID: 27720912 No abstract available.

8

Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease.

Ventham NT, Kennedy NA, Adams AT, Kalla R, Heath S, O'Leary KR, Drummond H; IBD BIOM consortium; IBD CHARACTER consortium; Wilson DC, Gut IG, Nimmo ER, Satsangi J. Ventham NT, et al. Nat Commun. 2016 Nov 25;7:13507. doi: 10.1038/ncomms13507. Nat Commun. 2016. PMID: 27886173 Free PMC article.

9

Advances in the understanding of mitochondrial DNA as a pathogenic factor in inflammatory diseases.

Boyapati RK, Tamborska A, Dorward DA, Ho GT. Boyapati RK, et al. F1000Res. 2017 Feb 20;6:169. doi: 10.12688/f1000research.10397.1. eCollection 2017. F1000Res. 2017. PMID: 28299196 Free PMC article. Review.

10

MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation.

Ho GT, Aird RE, Liu B, Boyapati RK, Kennedy NA, Dorward DA, Noble CL, Shimizu T, Carter RN, Chew ETS, Morton NM, Rossi AG, Sartor RB, Iredale JP, Satsangi J. Ho GT, et al. Among authors: boyapati rk. Mucosal Immunol. 2018 Jan;11(1):120-130. doi: 10.1038/mi.2017.31. Epub 2017 Apr 12. Mucosal Immunol. 2018. PMID: 28401939 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85 results

Search Page

Filters